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1. Introduction 
Many squamous cell carcinoma (SCC) of the head and neck presents with locally 
advanced disiease. In such cases, a combination chemotherapy of docetaxel, cisplatin, and 
5FU, followed by radiation improved their survival (Posner et al. 2007; Vermorken et al. 
2007). That is, addition of docetaxel to the combination of cisplatin and fluorouracil 
improves survival in head and neck squamous cell carcinoma. In a recent work to 
elucidate the possible mechanism, we investigated the effect of docetaxel on cell 
movement using head and neck cancer cell lines Hep2 and Ca9-22. Docetaxel treatment 
suppressed migration and invasiveness of head and neck cancer cells in vitro. We 
investigated the downstream effectors that control invasiveness after docetaxel 
administration in the present work.  
2. IC10 and IC50 in HEp-2 and Ca9-22 cells 
We used the same IC10 and IC50 concentrations (Table 1) (Kogashiwa et al. 2010) as our 
previous study. At IC10 concentrations, anti-proliferative effect was not observed. 
 
Cell line  IC10 IC50 
HEp-2 Cisplatin 2 µM 20 µM 
 Docetaxel 5 nM 23 nM 
Ca9-22 Cisplatin 10 µM 40 µM 
 Docetaxel 6 nM 11 nM 
Table 1  IC10 or IC50 values in two cells 
IC10 or IC50 values after 1 hour drug exposure followed by a 96 hours incubation in two head 
and neck cell lines. 
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3. Docetaxel inhibits the migration of head and neck cancer cells 
To assess cell migration a wound healing assay was employed. These results have been 
reported (Kogashiwa et al. 2010). Briefly, both in HEp-2 cell and CA9-22 cell, wound closure 
relative to no treatment condition is significantly reduced in docetaxel treatment while 
cisplatin treatment does not affect the cell migration (Fig.1.) (Kogashiwa et al. 2010). 
 
Fig. 1. Migration assay at IC10 in two head and neck cancer cell lines.  
Migration rate is compared to control cell migration rate. Each data point represents mean 
± SE. ***p < 0.001. 15 replicate were used in each experiments and experiments were 
repeated 4 times. 
4. Docetaxel inhibits the invasiveness of multicellular tumor spheroids.  
The similar results are obtained in three-dimensional multicellular tumor spheroid culture 
(Kogashiwa et al. 2010). At IC10 determined in monolayer culture, either cisplatin or 
docetaxel does not affect filopodia formation. However, at IC50 determined in monolayer 
culture, docetaxel, but not cisplatin, significantly decreases filopodia formation in HEp-2 
cells in spheroid culture (Fig.2.) (Kogashiwa et al. 2010). Taken together, In the previous 
study, we have shown that docetaxel, but not cisplatin inhibits cell migration both in 2D and 
3D culture. 
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Fig. 2. 3D gel culture of HEp-2 cell spheroids at IC50 concentration.  
HEp-2 cell spheroids were treated with cisplatin or docetaxel at IC50 followed by 96-hour 
incubation. bars= 250 µm. 4 replicate were used in each experiments and experiments were 
repeated 4 times. 
5. Tubulin bundle was formed by docetaxel treatment 
Taxanes, including docetaxel, function as a mitotic spindle toxin by inhibiting microtubule 
turnover. They bind to microtubules and enhance tubulin polymerization. We hypothesized 
that docetaxel may exert similar effect on cytosolic, non-centrisome associated microtubules 
resulting in decreased cell motility. We therefore examined the structure of microtubules as 
well as actin filaments. Consistent with previous observation, filopodia formation was less in 
docetaxel treatment compared to cisplatin treatment. But no gross abnormality was found in 
actin filament structure between the treatments. On the other hand, tubulin bundle formation 
was noted in docetaxel treatment but not in cisplatin treatment (Fig.3.). Then, we attempted to 
find the mechanism that connect deformed microtubule and decreased filopodia formation.  
 
Fig. 3. Staining of ┙-tubulin (by antibody) in HEp-2 cells treated by cisplatin, docetaxel or no 
treatment at IC50. Bars=50 µm. 3 replicate were used in each experiments and experiments 
were repeated 4 times. 
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6. Docetaxel inhibited Cdc42 activity 
Rho GTPases regulate many essential cellular processes, including actin dynamics, gene 
transcription, cell-cycle progression, cell adhesion, tumor progression and invasiveness 
(Hall 1998; Schmitz et al. 2000; Price et al. 2001). Among Rho-GTPases, Cdc42 is previously 
implicated in connecting microtubular input to actin filament organization (Cau et al. 2005). 
Cdc42 also promotes leading-edge extension through activation of Rac, which is implicated 
in formation of lamellipodia (Bishop et al. 2000). Thus, we examined activity of Cdc42, Rac 
and RhoA in the cells underwent cisplatin or docetaxel treatment, or no treatment. At IC10 
concentration, docetaxel significantly decreased Cdc42 and Rac activity in HEp-2 cells, but 
not RhoA activity (Fig.4.; cited from (Kogashiwa et al. 2010) with modification). Total 
amount of Cdc42, Rac and RhoA was not significantly different among these three 
conditions.  
It is reported that Cdc42 is activated in a thin band at cell edges extending filopodia 
(Nalbant et al. 2004). Consistent with the results of activity assay, Cdc42 localized at the 
plasma membrane was decreased after docetaxel treatment at IC10. Localization of Rac1 and 
RhoA had no apparent changes after treatment compared to control.  
 
Fig. 4. Colorimetric assay of Cdc42, Rac and RhoA activity in HEp-2 cells.  
The levels of activated Cdc42, Rac and RhoA in HEp-2 cell were evaluated immediately after 
1 hr of indicated treatment. Each data point represents mean ± SE. *p < 0.05, **p < 0.01. 
7. The molecules implicated in actin cytoskelton regulation were not 
significantly different between cisplatin and docetaxel treatment.  
Lamellipodia or filopodia formation was suppressed when cells were treated with docetaxel 
(fig.5.). Ezrin/radixin/moesin (ERM) proteins link the cortical cytoskeleton to the plasma 
membrane. In their active conformation (i.e. phosphorylated ERM), the N-terminal ERM 
domain binds to the cytoplasmic tails of transmembrane proteins, and the C-terminal ERM 
association domain binds to actin filaments. Using a p-ERM antibody, the levels of active 
ERM proteins were evaluated by Western blotting after no treatment, cisplatin or docetaxel 
treatment at IC10. There was no significant difference in the level of p-ERM among cisplatin, 
docetaxel and no treatment over a time course up to 48 hours (fig.6.). We also investigated 
the cofilin pathway as a regulator of the actin cytoskeleton. Cofilin is able to bind both G-
actin and F-actin, and regulated by LIM kinase 1 and its related kinases. The levels of cofilin 
(fig.6.) and LIMK1 (fig.6.) were evaluated over a time course of treatment at IC10. The levels 
of these proteins were not significantly different among  cisplatin, docetaxel and no 
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treatment, either. These results suggest that docetaxel treatment does not directly affect actin 
cytoskeleton remodeling. 
 
Fig. 5. Staining of F-actin (phalloidin) in HEp-2 cells treated by cisplatin, docetaxel or no 
treatment at IC50. Bars=50 µm. 3 replicate were used in each experiments and experiments 
were repeated 4 times. Arrows; filopodia 
 
Fig. 6. Time course of the levels of p-ERM, cofilin and LIMK in HEp-2 cells and Ca9-22 cells 
treated with cisplatin or docetaxel.  
┚-actin was probed for loding control. 3 replicate were used in each experiments and 
experiments were repeated 3 times. 
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8. Docetaxel treatment did not promote epithelial-mesenchymal transition 
(EMT) 
It has been well documented that many cancer cells lose most of their epithelial 
characteristics during progression and metastasis, through the process of EMT (Thiery 
2002). Generally, EMT causes increased motility and invasiveness of cancer cells due to 
decreased cell-cell adhesion. Snail, a zinc finger transcription factor, triggers EMT through 
direct repression of E-cadherin transcription (Batlle et al. 2000; Cano et al. 2000). The reverse 
correlation of snail and E-cadherin expression has been reported for various human cancers, 
including SCC (Yokoyama et al. 2001). Accordingly, we investigated the snail and E-
cadherin expression levels to assess whether cisplatin and/or docetaxel at IC10 differently 
influences EMT. Snail was decreasing over a time course (Fig.7.). Conversely E-cadherin was 
increasing over a time course (Fig.7.). But the levels of these proteins were not significantly 
different between cisplatin, docetaxel and no treatment. These results indicate that docetaxel 
treatment does not promote EMT at least in these cell lines. 
 
Fig. 7. Time course of snail and E-cadherin expression of HEp-2 cells and Ca9-22 cells 
treated with IC10 concentration of cisplatin or docetaxel.  
┚-actin was probed for loding control. 3 replicate were used in each experiments and 
experiments were repeated 3 times. 
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9. Matrix metalloproteinase (MMP) production was not significantly affected 
by cisplatin and docetaxel treatment  
MMPs are known to play an important role in extracellular matrix remodeling during the 
process of tumor invasion and metastasis (Egeblad et al. 2002). Two of these enzymes, 
MMP-2 and MMP-9, are potent gelatinases and have been correlated with the processes of 
invasion and metastasis of SCC (Sheu et al. 2003; Patel et al. 2005). Gelatin zymography 
revealed prominent 72000 dalton bands, corresponding to MMP2 secreted from the HEp-2 
and Ca9-22 cells. These bands appeared unchanged by either cisplatin or docetaxel 
treatment (Figure 8). 
 
Fig. 8. Gelatin zaymograpy. 
MMP secretion in HEp-2 cells and Ca9-22 cells after treatment or control were evaluated by 
Gelatin zymography. Gelatin zymography revealed prominent 72000 dalton bands, 
corresponding to MMP2 secreted from the HEp-2 and Ca9-22 cells. These bands appeared 
unchanged by either cisplatin or docetaxel treatment 
10. Discussion 
The metastatic process has traditionally been viewed as follows: (1) detachment of 
individual cells from the primary lesion (2) invasion of local stroma (3) entry of single cells 
or aggregates of tumor cells into blood vessels directly or via lymphatic channels 
(intravasation) (4) sticking to the vasculature distant from their origin followed by 
extravasation, and (5) invasion into the parenchyma of the target organ site. The newly 
formed lesions can themselves become the source of disseminating cells which repeat this 
cycle, giving rise to tertiary metastasis. Thus, Inhibition of invasion in the primary lesion 
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should result in preventing the distant metastasis. From this point of view, our results 
suggest that docetaxel, which decreased local invasiveness, may prevent distant metastasis. 
Although the effect of docetaxel on cell migration or invasiveness of ovary cancer cells 
(Bijman et al. 2008) and umbilical vein endothelial cells (Bijman et al. 2006) have been 
described, its effect on head and neck cancer cells has not been evaluated. 
Actin cytoskeleton provides the driving force for cell migration, while microtubules are 
required to establish cell polarity during motility in fibroblasts (Bershadsky et al. 1991). 
Actin is regulated by Rho family small GTPases, and it is indicated that microtubules may 
influence actin cytoskeleton through modulation of the activity  of Rho GTPases (Wittmann 
et al. 2001). Among Rho GTPases, cdc42 was reported to control the polarity of actin and 
microtubule through distinct signal transduction pathways (Cau et al. 2005). It is possible 
that the abnormal tubulin bundle induced by docetaxel lead to suppression of cdc42 
activity. This decreased cdc42 activity could affect actin filament and decrease the migration 
of the head and neck cancer cells.  
In contrast, we could not find definitive evidence for docetaxel to directly affect actin 
cytoskeleton regulation. It did not affect EMT processes or MMP production of these head 
and neck cancer cell lines. 
11. Conclusion 
 In conclusion, it is likely that docetaxel suppresses SCC migration through inhibition of 
microtubule turnover, which affects cdc42 activity and its subcellular localization leading to 
decreased filopodia formation. We propose that effect on cancer cell migration should be 
assessed together with anti-proliferative activity when evaluating a cancer 
chemotherapeutic agent. Along this line, we are now evaluating anti-migratory effect of 
EGFR tyrosine kinase inhibitors, another class of promising treatment for head and neck 
cancer. 
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